New hope for advanced endometrial cancer: major trial tests promising drug combo
NCT ID NCT05077215
Summary
This study aims to see if adding a new drug called EG-007 to the standard two-drug treatment (lenvatinib plus pembrolizumab) works better for women with advanced or recurrent endometrial cancer. It will enroll about 450 patients whose cancer has progressed after initial chemotherapy. The main goal is to see if the three-drug combination helps patients live longer without their cancer getting worse compared to the standard two-drug treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.